ACT wins FDA OK for second stem cell trial
This article was originally published in Scrip
Executive Summary
Advanced Cell Technology started 2011 off with a bang, with shares of the US biotech gaining as much as 25% in over-the-counter trading 3 January after it revealed that the US FDA gave the all clear for the firm to start the first ever clinical trial of an investigational human embryonic stem cell (hESC) therapy in patients with dry age-related macular degeneration (AMD).